Wen Wen

Wen Wen

Auto-generated profile, based on publicly available information

Wen Wen

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BLBerzenji Lawek
Berzenji Lawek
WWWen Wen
Wen Wen
SVStijn Verleden
Stijn Verleden
ECErik Claes
Erik Claes
SYSuresh Krishan Yogeswaran
Suresh Krishan Yogeswaran
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
In the last two decades, robotic-assisted thoracoscopic surgery (RATS) has gained popularity as a minimally invasive surgical (MIS) alternative to multi- and uniportal video-assisted thoracoscopic surgery (VATS). With this approach, the surgeon obviates the known drawbacks of conventional MIS, such as the reduced in-depth perception, hand-eye coordination, and freedom of motion of the instruments. Previous studies have shown that a robotic approach for operable lung cancer has treatment outcomes comparable to other MIS techniques such as multi-and uniportal VATS, but with less blood loss, a lower conversion rate to open surgery, better lymph node dissection rates, and improved ergonomics for the surgeon. The thoracic surgeon of the future is expected to perform more complex procedures. More patients will enter a multimodal treatment scheme making surgery more difficult due to severe inflammation. Furthermore, due to lung cancer screening programs, the number of patients presenting with operable smaller lung nodules in the periphery of the lung will increase. This, combined with the fact that segmentectomy is becoming an increasingly popular treatment for small peripheral lung lesions, indicates that the future thoracic surgeons need to have profound knowledge of segmental resections. New imaging techniques will help them to locate these lesions and to achieve a complete oncologic resection. Current robotic techniques exist to help the thoracic surgeon overcome these challenges. In this review, an update of the latest MIS approaches and nodule detection techniques will be given.

28 October 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
BLBerzenji Lawek
Berzenji Lawek
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
SVStijn Verleden
Stijn Verleden
SYSuresh Krishan Yogeswaran
Suresh Krishan Yogeswaran
WWWen Wen
Wen Wen
PSPaul Van Schil
Paul Van Schil
Lung ischemia–reperfusion injury (LIRI) remains a major contributor to perioperative morbidity and mortality in thoracic surgery, especially for lung transplantations, where it is one of the principal drivers of primary graft dysfunction (PGD). Although substantial advances have been made in surgical technique, donor management, and perioperative care, LIRI continues to pose a significant clinical challenge. Mechanistically, LIRI reflects a combined pathology of oxidative stress, endothelial and glycocalyx disruption, innate immune activation, mitochondrial dysfunction, and regulated cell death, resulting in loss of alveolar–capillary barrier integrity and gas exchange failure. Current management is phase-specific and multimodal, spanning donor care and preservation, controlled reperfusion and lung-protective ventilation, and pharmacological treatments. Treatment candidates that target oxidative stress and inflammatory cascades (e.g., antioxidants, complement and adenosine pathways, mesenchymal stromal cell products, and dipeptidyl-peptidase-4 inhibition) show promise, yet translation into a clinical scenario remains difficult. Increasing evidence supports endothelial-preserving and mitochondria-sparing strategies, rigorous perioperative bundles, and biomarker-guided trials to move from pathophysiology to practice. Ultimately, addressing LIRI requires an integrated, multidisciplinary approach that spans surgical, anesthetic, and pharmacologic domains, with the goal of improving both early outcomes and long-term graft survival in lung transplant patients.

25 April 2017 in Acta Chirurgica Belgica
Verified
Journal Article
Closed access
WWWen Wen
Wen Wen
BMBernard Majerus
Bernard Majerus
MMMarijke Van De Moortel
Marijke Van De Moortel
SLSalvatore Lobue
Salvatore Lobue
DFDidier Fobe
Didier Fobe
KSKurt Van Der Speeten
Kurt Van Der Speeten
Background: Abdominal wall hernias are a common problem. Composite meshes placed intraperitoneally for abdominal wall hernia repair are widely used. This registry evaluated the safety and efficacy of one specific composite mesh with polypropylene and expanded polytetrafluoroethylene (Intramesh® T1) in laparoscopic ventral hernia repair. Methods: A prospective multicentre registry with data from seven centres was collected between January 2013 and September 2014. Primary endpoint was recurrence rate at 12 months determined by clinical examination. Secondary outcome measures included intraoperative complications, complications during hospitalisation and at 1-month and 12-months follow-up. Results: The registry included 90 patients (30 female and 60 male). Fifty-five patients (61.1%) presented with primary ventral hernias and 35 patients (38.9%) with incisional ventral hernias. Median hernia size was 4 cm2. Intraoperative complications were reported in two patients (2.2%). Complications during hospitalisation were reported in four (4.4%) patients. At 1-month follow-up, 17 (18.9%) patients had postoperative complications, of which 5 complications were major and 19 were minor. Late complications at 12-months were observed in 10 patients (11.1%), of which 2 were major and 8 minor complications. Conclusion: Intramesh® T1 is a safe and effective composite mesh with favourable short and midterm outcome and morbidity. (NCT01816867)

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
SLSai-Lan Liu
Sai-Lan Liu
LTLin-Quan Tang
Lin-Quan Tang
QCQiu-Yan Chen
Qiu-Yan Chen
HLHuan-Xin Lin
Huan-Xin Lin
QYQi Yang
Qi Yang
LGLing Guo
Ling Guo
Background: To assess the prognosis of neck residue nasopharyngeal carcinoma (NPC) patients and the efficacy of neck dissection in the treatment of these patients.

12 September 2026 in American Journal of Transplantation
Verified
Journal Article
Open access
ACAxelle Coppens
Axelle Coppens
RBRahel Bodenmann
Rahel Bodenmann
JRJanik Riese
Janik Riese
HWHuijuan Wang
Huijuan Wang
MBMatthias Brunner
Matthias Brunner
SVStijn Verleden
Stijn Verleden

21 March 2019 in Acta Chirurgica Belgica
Verified
Journal Article
Closed access
WWW. Wen
W. Wen
GHG. H. Ho
G. H. Ho
EVE. J. Veen
E. J. Veen
HGH. G. W. de Groot
H. G. W. de Groot
MBM. G. Buimer
M. G. Buimer
LLL. van der Laan
L. van der Laan
Objective: To determine the effect of primary conservative treatment without revascularization in patients with proven aortoiliac occlusive disease (AIOD) presenting with intermittent claudication (IC). Background: The initial treatment of IC should focus on supervised exercise therapy (SET) and pharmacotherapy. Nowadays, primary endovascular revascularization (EVR) has become increasingly popular in patients with all types of AIOD. But in daily practice, EVR is often performed without initially extensive exercise. Method: This is a single centre retrospective study from December 2012 to September 2017. Primary outcomes were maximum walking distance (MWD) and patient satisfaction. Secondary outcomes were revascularization rate and mortality. Results: Twenty-four patients were included. Mean age was 64 years (SD: 9). Mean follow-up was 28 months (SD: 17). Nineteen patients (80%) had SET. In 18 (75%) patients, the MWD was improved compared to the initial situation. In five (21%) patients, the MWD stayed the same. The MWD of one (4%) patient decreased. Overall satisfaction rate was 87%. Three patients (13%) were not satisfied with the conservative treatment and eventually got an EVR. There was no disease related death. Conclusions: Conservative treatment, especially with SET, has acceptable subjective symptom outcomes in selected patients with AIOD. It could be a good alternative treatment for certain patients with AIOD and IC.